Skip to main content
Top
Published in: Metabolic Brain Disease 3/2016

01-06-2016 | Short Communication

Structural modeling of p.V31F variant in the aspartoacylase gene

Authors: Navaneethakrishnan Krishnamoorthy, Hatem Zayed

Published in: Metabolic Brain Disease | Issue 3/2016

Login to get access

Abstract

Aspartoacylase (ASPA) is an abundant enzyme in the brain, which catalyzes the conversion of N-acetylaspartate into acetate and aspartate, deficiency in its activity leads to degeneration of the white matter of the brain and is a recognized cause of Canavan disease (CD), which affect children. Although genotype-phenotype correlation have been reported for Canavan disease patients, this relationships is still not straightforward. In this communication, we use molecular modeling to address the structural consequences resulting from the missense variant p.V31F in the ASPA enzyme, which we previously reported in a homozygous form in an Egyptian patient with infantile CD. This modeling suggests that this variant brings significant changes to the catalytic core by introducing structural flexibility through neighbouring key residues. In particular, it provides a molecular explanation for the pathogenic effect of this variant and provides a meaningful genotype-phonotype relationships. The mutational impact appears to have an influence on the function of the protein and initiates molecular event for the mechanism of the disease.
Literature
go back to reference Baslow MH, Guilfoyle DN (2013) Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions. Biochimie 95:946–956CrossRefPubMed Baslow MH, Guilfoyle DN (2013) Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions. Biochimie 95:946–956CrossRefPubMed
go back to reference Baslow MH, Resnik TR (1997) Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms. J Mol Neurosci 9:109–125CrossRefPubMed Baslow MH, Resnik TR (1997) Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms. J Mol Neurosci 9:109–125CrossRefPubMed
go back to reference Bitto E, Bingman CA, Wesenberg GE, McCoy JG, Phillips GN Jr. (2007) Structure of aspartoacylase, the brain enzyme impaired in Canavan disease. Proc Natl Acad Sci U S A 104:456–461CrossRefPubMedPubMedCentral Bitto E, Bingman CA, Wesenberg GE, McCoy JG, Phillips GN Jr. (2007) Structure of aspartoacylase, the brain enzyme impaired in Canavan disease. Proc Natl Acad Sci U S A 104:456–461CrossRefPubMedPubMedCentral
go back to reference Gajendrarao P, Krishnamoorthy N, Kassem H, Moharem-Elgamal S, Cecchi F, Olivotto I, Yacoub MH (2013) Molecular modeling of disease causing mutations in domain C1 of cMyBP-C. PLoS One 8:e59206CrossRefPubMedPubMedCentral Gajendrarao P, Krishnamoorthy N, Kassem H, Moharem-Elgamal S, Cecchi F, Olivotto I, Yacoub MH (2013) Molecular modeling of disease causing mutations in domain C1 of cMyBP-C. PLoS One 8:e59206CrossRefPubMedPubMedCentral
go back to reference Hershfield JR, Pattabiraman N, Madhavarao CN, Namboodiri MA (2007) Mutational analysis of aspartoacylase: implications for Canavan disease. Brain Res 1148:1–14CrossRefPubMedPubMedCentral Hershfield JR, Pattabiraman N, Madhavarao CN, Namboodiri MA (2007) Mutational analysis of aspartoacylase: implications for Canavan disease. Brain Res 1148:1–14CrossRefPubMedPubMedCentral
go back to reference Jakobs C, ten Brink HJ, Langelaar SA, Zee T, Stellaard F, Macek M, Srsnova K, Srsen S, Kleijer WJ (1991) Stable isotope dilution analysis of N-acetylaspartic acid in CSF, blood, urine and amniotic fluid: accurate postnatal diagnosis and the potential for prenatal diagnosis of Canavan disease. J Inherit Metab Dis 14:653–660CrossRefPubMed Jakobs C, ten Brink HJ, Langelaar SA, Zee T, Stellaard F, Macek M, Srsnova K, Srsen S, Kleijer WJ (1991) Stable isotope dilution analysis of N-acetylaspartic acid in CSF, blood, urine and amniotic fluid: accurate postnatal diagnosis and the potential for prenatal diagnosis of Canavan disease. J Inherit Metab Dis 14:653–660CrossRefPubMed
go back to reference Kaul R, Casanova J, Johnson AB, Tang P, Matalon R (1991) Purification, characterization, and localization of aspartoacylase from bovine brain. J Neurochem 56:129–135CrossRefPubMed Kaul R, Casanova J, Johnson AB, Tang P, Matalon R (1991) Purification, characterization, and localization of aspartoacylase from bovine brain. J Neurochem 56:129–135CrossRefPubMed
go back to reference Kaul R, Gao GP, Balamurugan K, Matalon R (1993) Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat Genet 5:118–123CrossRefPubMed Kaul R, Gao GP, Balamurugan K, Matalon R (1993) Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat Genet 5:118–123CrossRefPubMed
go back to reference Le Coq J, Pavlovsky A, Malik R, Sanishvili R, Xu C, Viola RE (2008) Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue. Biochemistry 47:3484–3492CrossRefPubMedPubMedCentral Le Coq J, Pavlovsky A, Malik R, Sanishvili R, Xu C, Viola RE (2008) Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue. Biochemistry 47:3484–3492CrossRefPubMedPubMedCentral
go back to reference Makarova KS, Grishin NV (1999) The Zn-peptidase superfamily: functional convergence after evolutionary divergence. J Mol Biol 292:11–17CrossRefPubMed Makarova KS, Grishin NV (1999) The Zn-peptidase superfamily: functional convergence after evolutionary divergence. J Mol Biol 292:11–17CrossRefPubMed
go back to reference Matalon R, Michals-Matalon K (1993) Canavan disease. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K (eds) GeneReviews(R). University of Washington, Seattle. All rights reserved., Seattle (WA) Matalon R, Michals-Matalon K (1993) Canavan disease. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K (eds) GeneReviews(R). University of Washington, Seattle. All rights reserved., Seattle (WA)
go back to reference Matalon R, Kaul R, Michals K (1993) Canavan disease: biochemical and molecular studies. J Inherit Metab Dis 16:744–752CrossRefPubMed Matalon R, Kaul R, Michals K (1993) Canavan disease: biochemical and molecular studies. J Inherit Metab Dis 16:744–752CrossRefPubMed
go back to reference Matalon R, Michals K, Kaul R (1995) Canavan disease: from spongy degeneration to molecular analysis. J Pediatr 127:511–517CrossRefPubMed Matalon R, Michals K, Kaul R (1995) Canavan disease: from spongy degeneration to molecular analysis. J Pediatr 127:511–517CrossRefPubMed
go back to reference Matalon R, Rady PL, Platt KA, Skinner HB, Quast MJ, Campbell GA, Matalon K, Ceci JD, Tyring SK, Nehls M, Surendran S, Wei J, Ezell EL, Szucs S (2000) Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. J Gene Med 2:165–175CrossRefPubMed Matalon R, Rady PL, Platt KA, Skinner HB, Quast MJ, Campbell GA, Matalon K, Ceci JD, Tyring SK, Nehls M, Surendran S, Wei J, Ezell EL, Szucs S (2000) Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. J Gene Med 2:165–175CrossRefPubMed
go back to reference Moore RA, Le Coq J, Faehnle CR, Viola RE (2003) Purification and preliminary characterization of brain aspartoacylase. Arch Biochem Biophys 413:1–8CrossRefPubMed Moore RA, Le Coq J, Faehnle CR, Viola RE (2003) Purification and preliminary characterization of brain aspartoacylase. Arch Biochem Biophys 413:1–8CrossRefPubMed
go back to reference Surendran S, Michals-Matalon K, Quast MJ, Tyring SK, Wei J, Ezell EL, Matalon R (2003) Canavan disease: a monogenic trait with complex genomic interaction. Mol Genet Metab 80:74–80CrossRefPubMed Surendran S, Michals-Matalon K, Quast MJ, Tyring SK, Wei J, Ezell EL, Matalon R (2003) Canavan disease: a monogenic trait with complex genomic interaction. Mol Genet Metab 80:74–80CrossRefPubMed
go back to reference Zaki OK, El Abd HS, Mohamed SA, Zayed H (2015) Novel mutation in an Egyptian patient with infantile Canavan disease. Metab Brain Dis 30:1–5 Zaki OK, El Abd HS, Mohamed SA, Zayed H (2015) Novel mutation in an Egyptian patient with infantile Canavan disease. Metab Brain Dis 30:1–5
go back to reference Zeng BJ, Wang ZH, Ribeiro LA, Leone P, De Gasperi R, Kim SJ, Raghavan S, Ong E, Pastores GM, Kolodny EH (2002) Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease. J Inherit Metab Dis 25:557–570CrossRefPubMed Zeng BJ, Wang ZH, Ribeiro LA, Leone P, De Gasperi R, Kim SJ, Raghavan S, Ong E, Pastores GM, Kolodny EH (2002) Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease. J Inherit Metab Dis 25:557–570CrossRefPubMed
Metadata
Title
Structural modeling of p.V31F variant in the aspartoacylase gene
Authors
Navaneethakrishnan Krishnamoorthy
Hatem Zayed
Publication date
01-06-2016
Publisher
Springer US
Published in
Metabolic Brain Disease / Issue 3/2016
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-016-9796-z

Other articles of this Issue 3/2016

Metabolic Brain Disease 3/2016 Go to the issue